BRAF activating mutations occur in approximately 10% of metastatic colorectal cancers (CRCs) and are associated with poor prognosis in part due to an inferior response to high-dose 5-Flurouracil-based chemotherapy [1]. This evidence concerns the gene BRAF and metastatic colorectal cancer.